InMed Pharmaceuticals Free Cash Flow (FCF) History (INM)
InMed Pharmaceuticals reported −$7.0M in free cash flow for fiscal 2024, an increase of $448,088 from the previous fiscal year, with a free cash flow margin of −152.14%.
View full InMed Pharmaceuticals company overviewInMed Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-06-30 | −$7.0M | $448,088 | — | −152.14% |
| 2023 | 2023-06-30 | −$7.4M | $8.2M | — | −544.99% |
| 2022 | 2022-06-30 | −$15.6M | −$5.8M | — | −1143.90% |
| 2021 | 2021-06-30 | −$9.8M | −$2.4M | — | −514.30% |
| 2020 | 2020-06-30 | −$7.4M | — | — | — |
InMed Pharmaceuticals quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2024 | 2024-03-31 | −$1.9M | $969,593 | — | −164.96% |
| Q4 2022 | 2022-06-30 | −$4.0M | −$2.6M | — | — |
| Q3 2022 | 2022-03-31 | −$5.4M | −$3.8M | — | −1728.88% |
| Q2 2022 | 2021-12-31 | −$3.7M | −$1.7M | — | −1413.94% |
| Q1 2022 | 2021-09-30 | −$2.9M | −$506,367 | — | — |
| Q4 2020 | 2020-06-30 | −$1.4M | — | — | — |
| Q3 2020 | 2020-03-31 | −$1.5M | — | — | — |
| Q2 2020 | 2019-12-31 | −$2.1M | — | — | — |
| Q1 2020 | 2019-09-30 | −$2.4M | — | — | — |
InMed Pharmaceuticals free cash flow growth trends
InMed Pharmaceuticals's latest reported quarter, Q3 2024, generated −$1.9M in free cash flow, an increase of $969,593 year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review InMed Pharmaceuticals filings at SEC.gov ↗